The closing price of Inovio Pharmaceuticals Inc (NASDAQ: INO) was $12.41 for the day, down -5.41% from the previous closing price of $13.12. In other words, the price has decreased by -$0.71 from its previous closing price. On the day, 526339 shares were traded. INO stock price reached its highest trading level at $13.38 during the session, while it also had its lowest trading level at $12.12.
Ratios:
Our analysis of INO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.60 and its Current Ratio is at 3.60. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.09.
BofA Securities Downgraded its Neutral to Underperform on November 01, 2022, while the target price for the stock was maintained at $2.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 05 ’23 when Zoth Lota S. sold 5,700 shares for $0.56 per share. The transaction valued at 3,192 led to the insider holds 52,716 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INO now has a Market Capitalization of 306.85M and an Enterprise Value of 191.77M. For the stock, the TTM Price-to-Sale (P/S) ratio is 349.42 while its Price-to-Book (P/B) ratio in mrq is 2.41. Its current Enterprise Value per Revenue stands at 230.49 whereas that against EBITDA is -1.47.
Stock Price History:
Over the past 52 weeks, INO has reached a high of $14.75, while it has fallen to a 52-week low of $3.89. The 50-Day Moving Average of the stock is 8.80, while the 200-Day Moving Average is calculated to be 6.35.
Shares Statistics:
INO traded an average of 562.63K shares per day over the past three months and 537.59k shares per day over the past ten days. A total of 23.37M shares are outstanding, with a floating share count of 22.98M. Insiders hold about 1.65% of the company’s shares, while institutions hold 17.93% stake in the company. Shares short for INO as of Mar 15, 2024 were 2.06M with a Short Ratio of 3.66, compared to 1.74M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.81% and a Short% of Float of 8.87%.
Earnings Estimates
The firm’s stock currently is rated by 4 analysts. On average, analysts expect EPS of -$0.99 for the current quarter, with a high estimate of -$0.86 and a low estimate of -$1.17, while EPS last year was -$1.92. The consensus estimate for the next quarter is -$0.97, with high estimates of -$0.82 and low estimates of -$1.15.
Analysts are recommending an EPS of between -$3.2 and -$4.64 for the fiscal current year, implying an average EPS of -$3.93. EPS for the following year is -$3.39, with 3 analysts recommending between -$2.85 and -$4.41.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $250k to a low estimate of $100k. As of the current estimate, Inovio Pharmaceuticals Inc’s year-ago sales were $114k, an estimated increase of 66.70% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $190k, a decrease of -15.90% less than the figure of $66.70% in the same quarter last year. There is a high estimate of $250k for the next quarter, whereas the lowest estimate is $100k.
